Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

First Patient Of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
Ethicon Endo-Surgery, Inc. announced the successful treatment of the first patient of its IDE feasibility trial. The case, which was performed at The Ohio State University Center for Minimally Invasive Surgery, marks the first natural orifice translumenal endoscopic surgery (NOTES) procedure involving the company"s investigational devices. NOTES is a surgical method in which external incisions are eliminated, potentially leading to reduced pain, a quicker recovery and a faster return to normal activities for the patient.
generic viagra online
Lancet Infectious Diseases Examines Spread Of XDR-TB
The journal Lancet Infectious Diseases examines the worldwide spread of extensively drug-resistant tuberculosis (XDR-TB). Currently, about 500,000 of the 9 million new cases of TB that are identified each year are strains of XDR-TB. "Drug resistance is largely man-made - it is vitally important to review antibiotic treatment strategies and to ensure the Stop TB Strategy is fully applied to prevent further selection of drug-resistant mutants," Leonard Amaral of Universidade Nova de Lisboa said.
News of the day
2009/044 NICE Issues Final Guidance On The Use Of Rituximab For First Line Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published guidance on the use of rituximab for the first line treatment of chronic lymphocytic leukaemia. The guidance recommends that rituximab should be considered asa possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide.
Medical Devices

Possible Government Rethink On NHS Private Finance Initiative Welcomed By UNITE, UK

A possible government rethink into the "flawed and expensive" private financing of NHS hospitals has been welcomed by Unite, the largest union in the country. Unite, which is campaigning strongly against the privatisation of the NHS, was commenting on an interview by health minister, Lord Darzi in which he said the Private Finance Initiative (PFI) "needs to be looked at." Lord Darzi told BMA News: "That model of funding may have been the right model but I have no doubt that the Department (of Health) will be appraising whether that it is still the model for the future or whether there are other, better models." "Quality is a moving target and PFIs have been very successful and might be in the future but it needs to be looked at." Unite National Officer for Health, Karen Reay said: "At long last, the government is beginning to realise that PFI is a flawed and expensive exercise that continues to consume billions of pounds in costly contracts for the enormous profit of private companies. This is money that could be better spent on frontline services for patients and clients." "Lord Darzi comments are to be welcomed - there is a chink of light at the end of the tunnel. However, when he talks about "better models for the future", we hope he means that the PFI experiment is abandoned, and not that the whole sorry process should be accelerated. We shall be seeking clarification from government on this point." Karen Reay welcomed the results of a BMA News survey which revealed that more than 90% of doctors were worried about the future of their local health services if they were left to market forces. She said: "This shows that right across the health service from GPs to health visitors to ambulance staff there is a broad coalition of health professionals opposed to the creeping tide of marketisation of the NHS." The Patchwork Privatisation of Our Health Service - a special report can be downloaded from http://www.unitetheunion.com/health and then clicking on Unite Health Sector web page: http://www.unitetheunion.com/health. Unite The Union


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009